Abstract
Background and importanceA large number of patients with systemic autoimmune diseases (SAD) do not respond or relapse to firstline therapies. Current guidelines recommend the off-label use of rituximab for many...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
